Does Buspirone Make You Lose Weight?

Buspirone is not established as a weight-loss drug, and the clinical evidence that it causes meaningful weight loss in humans is thin. Prescribed primarily for generalized anxiety disorder, buspirone has a relatively neutral weight profile compared to many other psychiatric medications, which is partly why the question comes up so often. Some animal research points to a possible fat-reduction mechanism, and some users report appetite changes, but the leap from those observations to “buspirone helps you lose weight” is one the science has not made.

What Happens to Appetite and Weight in People Taking Buspirone

The most relevant human evidence about buspirone and body weight comes not from weight-loss studies but from clinical trials designed to test buspirone against other anxiety drugs. In one controlled trial comparing buspirone to the benzodiazepine alprazolam for generalized anxiety, the buspirone group most frequently reported gastrointestinal side effects, including appetite disturbances and abdominal complaints.¹ The term “appetite disturbances” is deliberately vague because it cuts both ways. Some people on buspirone eat less because they feel nauseous or have stomach discomfort. Others report increased appetite. The FDA-approved labeling for buspirone lists both decreased appetite and increased appetite as reported side effects, each occurring in a small minority of patients.

This ambiguity is the central reality of buspirone and weight. The drug does not push appetite strongly in one direction the way, say, mirtazapine pushes it up or topiramate pushes it down. When people do notice a change, the nausea and GI upset that buspirone can cause early in treatment may temporarily suppress appetite and lead to a few pounds of weight loss. But that effect tends to fade as the body adjusts, usually within the first couple of weeks.

The Animal Research That Suggests Fat Reduction

A 2023 study in spontaneously hypertensive rats found something more dramatic. Rats treated with buspirone at a 10 mg dose showed decreases in both body weight and abdominal fat weight compared to untreated rats. The same treatment also lowered triglycerides, reduced blood pressure, and increased HDL cholesterol.² The researchers proposed that buspirone activates a metabolic pathway involved in energy production and fat breakdown, which in turn could explain the weight and fat loss they observed. In cell cultures, buspirone also reduced lipid accumulation in fat cells at higher concentrations.²

These results sound promising if you read them in isolation. But the rats in this study were a very specific strain bred to have high blood pressure and metabolic abnormalities. They are not a stand-in for healthy humans or even for the typical person taking buspirone for anxiety. The dose scaling between a rat and a human is not straightforward, and the metabolic pathway the researchers identified has not been confirmed to activate in the same way in people taking standard clinical doses of buspirone. This study generated an interesting hypothesis, not a treatment finding.

The Contradictory Finding on Food Intake

Confusingly, other animal studies have found that buspirone can increase eating. Research on dose-related effects showed that a low dose of buspirone increased food intake in animals after both single and repeated administration, though higher doses did not have the same effect.³ Earlier work found that buspirone, along with related compounds, can stimulate feeding behavior in rats, though the researchers noted that buspirone’s appetite-stimulating effect appeared to work through a different mechanism than its chemical relatives. Specifically, when researchers depleted serotonin from the rats’ brains, the feeding effects of the related drugs disappeared but buspirone’s feeding effect persisted, suggesting buspirone was triggering appetite through something other than serotonin.⁴

So in animal models, buspirone has been shown to both increase food intake (at low doses, through a non-serotonin pathway) and decrease body weight and fat (in hypertensive rats, through a metabolic pathway). These are not necessarily contradictory: a drug could theoretically boost appetite while also speeding up fat metabolism, resulting in no net weight change or even weight loss. But the practical takeaway is that the preclinical picture is messy, and no single animal finding can reliably predict what will happen to your weight.

How Buspirone Compares to Other Psychiatric Medications

One reason buspirone’s weight profile gets attention is the contrast with alternatives. Many medications used for anxiety and related conditions are associated with weight gain. SSRIs like paroxetine are linked to gradual weight increase over months. Benzodiazepines can lead to weight gain partly through sedation and reduced physical activity. Atypical antipsychotics sometimes used off-label for anxiety, like quetiapine, are among the most weight-promoting psychiatric drugs available. Against that backdrop, buspirone stands out because it tends not to cause significant weight gain.

“Weight neutral” is the term clinicians often use, and it is probably the most accurate characterization. This does not mean your weight will not change at all while taking buspirone. It means the drug itself is not systematically pushing your weight up or down in the way those other medications do. For someone switching from a medication that caused weight gain, starting buspirone might coincide with losing some of the weight they had put on, which could create the impression that buspirone itself caused the loss.

That distinction matters because online forums are full of anecdotes from people who lost weight “on buspirone” without distinguishing between weight lost because of buspirone and weight lost after discontinuing a weight-promoting drug. If you are gaining weight on an SSRI and your doctor switches you to buspirone, any subsequent weight loss is likely a withdrawal of the previous drug’s effect rather than an active slimming property of buspirone.

The Cortisol Question

Buspirone has a well-documented short-term effect on cortisol, the body’s primary stress hormone. Studies in both healthy volunteers and people with depression have found that buspirone increases cortisol levels acutely after a dose.⁵ This happens because buspirone acts on serotonin receptors that are involved in regulating the hormonal stress response, and stimulating those receptors can temporarily boost the release of stress hormones.⁶

If you have read anything about cortisol and weight, you might be alarmed: chronically elevated cortisol is associated with fat storage, particularly around the abdomen. But the cortisol spike from buspirone is acute, meaning it happens after each dose and fades. It is not the same as the sustained, grinding cortisol elevation seen in conditions like Cushing’s syndrome. There is no evidence that the transient cortisol bumps from buspirone lead to fat accumulation over time. If anything, some researchers have speculated in the opposite direction, that buspirone’s engagement with stress-response pathways could modulate metabolism in complex ways, but this remains speculative. The cortisol effect is worth knowing about, but it should not be a reason to expect weight gain.

The Dopamine Angle

Buspirone is primarily classified as a serotonin receptor agonist, but it also has meaningful activity at dopamine receptors. A PET imaging study in humans found that buspirone modestly blocks dopamine D2 and D3 receptors, with maximal occupancy of roughly 25% even at doses well above what is typically prescribed.⁷ Separate research in rats found that buspirone’s effects on brain metabolism resemble those of dopamine D2 antagonists.⁸

This matters for the weight discussion because strong D2 antagonism is one of the mechanisms by which antipsychotic drugs promote weight gain. But buspirone’s dopamine blockade is modest. At standard clinical doses (typically 15 to 30 mg per day), the D2 and D3 occupancy is likely even lower than the 25% seen at high doses in the imaging study. That level of dopamine interaction probably is not enough to meaningfully alter appetite or metabolism in most people, which is consistent with buspirone’s generally weight-neutral reputation.

Pharmacovigilance Data and What Rare Reports Tell Us

Large post-marketing safety databases collect adverse event reports from real-world use, and they occasionally turn up signals that clinical trials were too small to detect. A pharmacovigilance study using the FDA’s adverse event reporting system identified a small but noteworthy signal for abnormal body weight associated with buspirone, including 19 reports of obesity.⁹ Nineteen cases out of the vast number of people who have taken buspirone over the decades is a very small number. And these reports cannot establish that buspirone caused the weight gain, only that it was reported by or about someone taking the drug.

Still, this finding is interesting because it leans in the opposite direction from the weight-loss narrative. It suggests that if buspirone does affect weight in rare individual cases, the direction could go either way. Some people might lose a few pounds due to GI side effects or anxiety reduction (less stress eating), while a small number might gain weight for reasons that are not well understood. Neither pattern is common enough to dominate the drug’s profile.

Why Anxiety Treatment Itself Affects Weight

Something that gets overlooked in these discussions is how effectively treating anxiety can independently change eating patterns. Anxiety itself has unpredictable effects on weight. Some people eat more when anxious, using food as comfort or distraction. Others lose their appetite entirely when their anxiety is high. When buspirone works and anxiety decreases, whatever eating pattern anxiety was driving tends to normalize.

A person who was overeating due to anxiety may find they naturally eat less once their anxiety is better managed. They might attribute the resulting weight loss to buspirone when it was really the relief from anxiety that changed their behavior. Conversely, someone whose anxiety was suppressing their appetite might start eating more normally once the anxiety lifts, and they could gain weight even though the drug itself is weight-neutral. Separating the drug’s pharmacological effect on weight from the behavioral changes that come with successful anxiety treatment is nearly impossible in everyday life, which is one reason anecdotal reports about buspirone and weight are so inconsistent.

Practical Considerations if You Are Concerned About Weight

If you are starting buspirone and worried about weight changes, a few things are worth keeping in mind. The nausea and stomach upset that sometimes occur in the first week or two can temporarily reduce appetite, but these effects usually resolve. If you notice a drop on the scale during that early period, it is likely temporary and related to eating less while you adjust. Conversely, if you gain a few pounds in the first couple of months, look at whether your eating habits have changed alongside your anxiety levels before blaming the medication.

Tracking your weight periodically and keeping a rough food journal for the first couple of months can help distinguish a drug effect from a behavioral shift. If you notice a sustained, unexplained change of more than a few pounds in either direction after three or four months on buspirone, that is worth mentioning to your prescriber. But the most common outcome, based on the overall weight of the evidence, is that buspirone will not significantly move the number on your scale.

Buspirone’s Receptor Profile and Why Predicting Weight Effects Is Hard

Part of the difficulty in pinning down buspirone’s weight effects comes from its unusually complicated pharmacology. Most psychiatric drugs act on one or two receptor systems in a fairly predictable way. Buspirone touches serotonin 5-HT1A receptors (its primary mechanism for anxiety), dopamine D2 and D3 receptors (modestly), and through its metabolites, additional receptor systems. Each of these receptor types plays some role in appetite, metabolism, or energy balance, but they can pull in different directions.

Stimulating 5-HT1A receptors can increase appetite in some contexts, as demonstrated in the animal feeding studies.¹⁰ Blocking D2 receptors can promote weight gain at high levels of occupancy. But activating metabolic pathways like the one identified in the rat study could promote fat burning. In a single person taking a single dose, all of these effects are happening simultaneously at different magnitudes, and the net result depends on genetics, dose, diet, activity level, and which effect happens to dominate. This is why two people on the same dose of buspirone can report opposite experiences with their weight, and why neither of them is wrong about what happened to them personally.

The honest state of the science is that we do not have large, well-controlled human studies specifically designed to measure buspirone’s effect on weight. What we have is a patchwork of animal research pointing in multiple directions, side-effect reports from clinical trials designed for other purposes, and a pharmacovigilance database that picks up rare signals but cannot prove causation. Until someone runs a dedicated trial, the best summary remains that buspirone is unlikely to cause significant weight loss or gain in most people, but individual variation is real and not well predicted by any test currently available.